AntibioticDB

Kibdelomycin

Bacterial topoisomerase inhibitor

Merck Research Laboratories, USA

2011

Highest development stage: Preclinical
Development active
Gram-positive activity
Propensity to select resistant bacteria
Mechanism of Action/Target pathogen: Clostridium difficile infections (CDI)
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11016
Citation (1): http://aac.asm.org/content/58/4/2387.full
Citation (2): http://www.sciencedirect.com/science/article/pii/S107455211100233X
Citation (3): https://www.ncbi.nlm.nih.gov/pubmed/25845866
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/71463014